Gilead Sciences, Inc.

Gilead Pharmasset LLC

Nathan D Shapiro

Darryl Kato

Jeromy J Cottell

Zheng-Yu Yang

Scott D Schroeder

Elbert Chin

John O Link

James G Taylor

Michael L Mitchell

Elizabeth M Bacon

Teresa Alejandra Trejo Martin

Ashley Anne Katana

Jiayao Li

Qiaoyin Wu

Hyung-Jung Pyun

Lan Jiang

Dustin S Siegel

Hong Yang

Jennifer R Zhang

Hongyan Guo

Nathan E Wright

Chienhung Chou

Ana Zurisadai Gonzalez Buenrostro

Hang Chu

Xiaochun Han

Chao-I Hung

Devleena M Shivakumar

Sheila M Zipfel

Gediminas J Brizgys

Adam James Schrier

Michael Sangi

Bruce Ross

Ruben Martinez

Kapil Kumar Karki

Rhiannon Thomas-Tran

Gregg M Schwarzwalder

Jonathan Clive Tripp

Katie Ann Keaton

Andrew W Waltman

Suzanne M Szewczyk

Troy Evan Reynolds

Denise A Colby

James S Cassidy

Kavoos Kolahdouzan

Johann Chan

Dominika Pcion

Lina Chan

Donald Tang

Amy Cagulada

Chris Levins

Adam Littke

Pamela Seng

Lawrence Yu

Richard L Mackman

Michael Graupe

Kevin S Currie

Winston C Tse

Eda Y Canales

Hon Chung Hui

Samuel E Metobo

Michael R Mish

Hai Yang

Roland D Saito

Gregory F Chin

Mark J Bartlett

David W Lin

Evangelos Aktoudianakis

Yunfeng Eric Hu

Stephen E Ammann

Michael O Clarke

Jennifer Leigh Cosman

Bindu Goyal

Doris T Tang

Daniel G Shore

Ezra Roberts

Deeba Ensan

Gregg M Schwarzwälder

Megan K Armstrong

Stephen Ho

Sudha Kondappally

Sudha Kondapally

Troy Reynolds

Jonathan Tripp

Ana Z Gonzalez Buenrostro

The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

HIV inhibitor compounds

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, L, W, W, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

The present disclosure provides pyrimidine dione compounds of Formula I

CD73 compounds

The invention provides a compound of Formula I:

The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.

Anti-HIV compounds

The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.

Compounds for the treatment of hepatitis B virus infection

The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.

Synthesis of an antiviral compound

Growing community of inventors

Belmont, CA, United States of America

Nathan D Shapiro